Новые стратегии в лечении рефрактерных форм и рецидивов фолликулярной лимфомы: терапия Т-лимфоцитами с химерным антигенным рецептором

Введение. Фолликулярная лимфома (ФЛ) — самая частая индолентная лимфома. Несмотря на продолжительную общую выживаемость, опухоль остается неизлечимой у большинства больных. Не существует алгоритма выбора лечения ФЛ после 3 линий терапии. Терапия Т-лимфоцитами с химерным антигенным рецептором (chimeric antigen receptor, СAR) оказалась эффективной при ФЛ.

Цель: систематизировать данные об эффективности и безопасности современной CAR T терапии при ФЛ.

Основные сведения. CAR T терапия — это лечебная опция для больных ФЛ как после множества курсов терапии, так и с первично рефрактерной опухолью. Продолжается совершенствование этого метода, улучшается безопасность и расширяются возможности использования, проводится интеграция CAR T терапии в противорецидивные схемы ФЛ.

1. Morton L.M., Wang S.S., Devesa S.S., et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107(1):265–76. DOI: 10.1182/blood-2005-06-2508.

2. Watanabe T., Tobinai K., Wakabayashi M., et al. R-CHOP treatment for patients with advanced follicular lymphoma: Over 15-year follow-up of JCOG0203. Br J Haematol. 2024;204(3):849–60. DOI: 10.1111/bjh.19213.

3. Ghione P., Palomba M.L., Ghesquieres H., et al. Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study. Haematologica. 2023;108(3):822–32. DOI: 10.3324/ HAEMATOL.2022.281421.

4. Casulo C., Dixon J.G., Le-Rademacher J., et al. Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. Blood. 2022;139(11):1684–93. DOI: 10.1182/blood.2020010263.

5. Metzner B., Pott C., Müller T.H., et al. Long‐term outcome in patients with follicular lymphoma following high‐dose therapy and autologous stem cell transplantation. Eur J Haematol. 2021;107(5):543–52. DOI: 10.1111/ejh.13691.

6. Jiménez-Ubieto A., Grande C., Caballero D., et al. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure. Biol Blood Marrow Transplant. 2017;23(10):1631–40. DOI: 10.1016/j.bbmt.2017.05.021.

7. Смольянинова А.К., Беляева А.В., Сидорова Ю.В. и др. Высокодозная химиотерапия с трансплантацией аутологичных гемопоэтических стволовых клеток в первой линии терапии фолликулярной лимфомы. Гематология и трансфузиология. 2023;68(3):344–62. DOI: 10.35754/0234-5730-2023-68-3-344-362.

8. Giraudo M., Jackson Z., Das I., et al. Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin’s Lymphoma. Pathogens and Immunity. 2024;9(1):1–17. DOI: 10.20411/pai.v9i1.647.

9. Гаврилина О.А., Галстян Г.М., Щекина А.Е. и др. Терапия Т-клетками с химерным антигенным рецептором взрослых больных В-клеточными лимфопролиферативными заболеваниям. Гематология и трансфузиология. 2022;67(1):8–28. DOI: 10.35754/0234-5730-2022-67-1-8-28.

10. Jacobs R., Jacobson C. The treatment of follicular lymphoma with CD19-directed chimeric antigen receptor T-cell therapy. Front Oncol. 2024;14:1384600. DOI: 10.3389/fonc.2024.1384600.

11. Fowler N.H., Chavez J.C., Riedell P.A. Moving T-Cell Therapies into the Standard of Care for Patients with Relapsed or Refractory Follicular Lymphoma: A Review. Target Oncol. 2024;19(4):495–510. DOI: 10.1007/s11523-024-01070-z.

12. Thiruvengadam S.K., Shouse G., Danilov A. V. Thinking “outside the germinal center”: Re-educating T cells to combat follicular lymphoma. Blood Rev. 2023;61:101099. DOI: 10.1016/j.blre.2023.101099.

13. Perica K., Curran K.J., Brentjens R.J., et al. Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center. Biol Blood Marrow Transplant. 2018;24(6):1135–41. DOI: 10.1016/j.bbmt.2018.02.018.

14. Ayala Ceja M., Khericha M., Harris C.M., et al. CAR-T cell manufacturing: Major process parameters and next-generation strategies. J Exp Med. 2024;221(2):e20230903. DOI: 10.1084/jem.20230903.

15. Lickefett B., Chu L., Ortiz-Maldonado V., et al. Lymphodepletion — an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle. Front Immunol. 2023;14: 1303935. DOI: 10.3389/fimmu.2023.1303935.

16. Chong E.A., Chong E.R., Therwhanger D., et al. Bendamustine as Lymphodepletion for Brexucabtagene Autoleucel Therapy of Mantle Cell Lymphoma. Transplant Cell Ther. 2024;30(7):726.e1–e8. DOI: 10.1016/j.jtct.2024.03.015.

17. Ghilardi G., Chong E.A., Svoboda J., et al. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas. Ann Oncol. 2022;33(9):916–28. DOI: 10.1016/j.annonc.2022.05.521.

18. Eshhar Z., Waks T., Gross G., et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Nat Acad Sci. 1993;90(2):720–4. DOI: 10.1073/pnas.90.2.720.

19. Till B.G., Jensen M.C., Wang J., et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112(6):2261–71. DOI: 10.1182/blood-2007-12-128843.

20. Kershaw M.H., Westwood J.A., Parker L.L., et al. A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer. Clin Cancer Res. 2006;12(20):6106–15. DOI: 10.1158/1078-0432.CCR-06-1183.

21. van der Stegen S.J.C., Hamieh M., Sadelain M. The pharmacology of second-generation chimeric antigen receptors. Nat Rev Drug Disccov. 2015;14(7):499– 509. DOI: 10.1038/nrd4597.

22. Savoldo B., Ramos C.A., Liu E., et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients. J Clin Invest. 2011;121(5):1822–6. DOI: 10.1172/JCI46110.

23. Abramson J.S., Palomba M.L., Gordon L.I., et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839– 52. DOI: 10.1016/S0140-6736(20)31366-0.

24. Wang M., Munoz J., Goy A., et al. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. N Engl J Med. 2020;382(14):1331–42. DOI: 10.1056/NEJMOA1914347.

25. Locke F.L., Ghobadi A., Jacobson C.A., et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 2019;20(1):31–42. DOI: 10.1016/S1470-2045(18)30864-7.

26. Schuster S.J., Bishop M.R., Tam C.S., et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019;380(1):45– 56. DOI: 10.1056/nejmoa1804980.

27. Kochenderfer J.N., Wilson W.H., Janik J.E., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099–102. DOI: 10.1182/BLOOD-2010-04-281931.

28. Cappell K.M., Sherry R.M., Yang J.C., et al. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. J Clin Oncol. 2020;38(32):3805–15. DOI: 10.1200/JCO.20.01467.

29. Schuster S.J., Svoboda J., Chong E.A., et al. Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. N Engl J Med. 2017;377(26):2545–54. DOI: 10.1056/NEJMoa1708566.

30. Kochenderfer J.N., Dudley M.E., Kassim S.H., et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540–9. DOI: 10.1200/JCO.2014.56.2025.

31. Jacobson C.A., Chavez J.C., Sehgal A.R., et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022;23(1):91–103. DOI: 10.1016/s1470-2045(21)00591-X.

32. Schuster S.J., Fowler N., Dickinson M., et al. Clinical Outcomes of Patients with Relapsed/Refractory Follicular Lymphoma Treated with Tisagenlecleucel: Phase 2 Elara 3-Year Follow-up. Blood. 2023;142(Suppl. 1):601. DOI: 10.1182/ blood-2023-180936.

33. Solal-Celigny P. Follicular Lymphoma International Prognostic Index. Blood. 2004;104(5):1258–65. DOI: 10.1182/blood-2003-12-4434.

34. Neelapu S.S., Chavez J.C., Sehgal A.R., et al. Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 4-Year Follow-up from the Phase 2 ZUMA-5 Trial. Blood. 2023;142(Supplement 1):4868. DOI: 10.1182/blood-2023-174914.

35. Zelenetz A.D., Gordon L.I., Abramson J.S., et al. NCCN Guidelines Insights: BCell Lymphomas, Version 3.2019. J Natl Compr Cancer Netw. 2019;17(6):650– 61. DOI: 10.6004/jnccn.2019.0029.

36. Fowler N.H., Dickinson M., Dreyling M., et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022;28(2):325–32. DOI: 10.1038/s41591-021-01622-0.

37. Mor V., Laliberte L., Morris J.N., et al. The Karnofsky performance status scale: An examination of its reliability and validity in a research setting. Cancer. 1984;53(9):2002–7. DOI: 10.1002/1097-0142(19840501)53:9<2002::AIDCNCR2820530933>3.0.CO;2-W.

38. Azoulay É., Castro P., Maamar A., et al. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. Lancet Haematol. 2021;8(5):e355–64. DOI: 10.1016/S2352-3026(21)00060-0.

39. Щекина А.Е., Галстян Г.М., Гаврилина О.А., и др.. Синдром высвобождения цитокинов и другие осложнения после терапии Т-лимфоцитами с химерным антигенным рецептором у взрослых с В-клеточными лимфомами и лейкозами. Гематология и трансфузиология. 2022;67(S2.):88.

40. Neelapu S.S., Tummala S., Kebriaei P., et al. Chimeric antigen receptor Tcell therapy — assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47–62. DOI: 10.1038/nrclinonc.2017.148.

41. Kymriah® (tisagenlecleucel) [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2022.

42. Yescarta® (axicabtagene ciloleucel) [package insert]. Santa Monica (CA): Kite Pharma, Inc.; 2022.

43. Adkins, S. CAR T-Cell Therapy: Adverse Events and Management. J Adv Pract Oncol. 2019;10(Suppl 3): 21–28. DOI: 10.6004/jadpro.2019.10.4.11.

44. Jacobson C.A., Hemmer M.T., Hu Z.-H., et al. Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL). J Clin Oncol. 2023;41(16_suppl):7509. DOI: 10.1200/JCO.2023.41.16_suppl.7509.

45. Ghafouri S., Fenerty K., Schiller G., et al. Real-World Experience of Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed or Refractory Aggressive B-cell Lymphomas: A Single-Institution Experience. Clin Lymphoma Myeloma Leuk. 2021;21(12):861–72. DOI: 10.1016/j.clml.2021.07.002.

46. Kwon M., Iacoboni G., Reguera J.L., et al. Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma. Haematologica. 2022;108(1):110–21. DOI: 10.3324/haematol.2022.280805.

47. Dickinson M., Martinez-Lopez J., Jousseaume E., et al. Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma. Leuk Lymph. 2024;65(3):323–32. DOI: 10.1080/10428194.2023.2289854.

48. Flinn I.W., Jacobson C.A., Nastoupil L.J., et al. ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-ofcare therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL). J Clin Oncol. 2023;41(16_suppl):TPS7579. DOI: 10.1200/JCO.2023.41.16_suppl.TPS7579.

49. Ghione P., Palomba M.L., Patel A.R., et al. Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Blood. 2022;140(8):851–60. DOI: 10.1182/blood.2021014375.

50. Salles G., Schuster S.J., Dreyling M., et al. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma. Blood Adv. 2022;6(22):5835–43. DOI: 10.1182/bloodadvances.2022008150.

51. Visco C., Chiappella A., Nassi L., et al. Rituximab, bendamustine, and lowdose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol. 2017;4(1):e15–23. DOI: 10.1016/S2352-3026(16)30185-5.

52. Neelapu S.S., Chavez J., Sehgal A.R., et al. 3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). Blood. 2022;140(Supplement 1):10380–3. DOI: 10.1182/blood-2022-156120.

53. Iacoboni G., Navarro V., Martín-López A.Á., et al. Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With 1984;53(9):2002–7. DOI: 10.1002/1097-0142(19840501)53:9<2002::AIDCNCR2820530933>3.0.CO;2-W.

54. Yakoub-Agha I., Chabannon C., Bader P., et al. Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). Haematologica. 2020;105(2):297–316. DOI: 10.3324/haematol.2019.229781.

55. Casulo C., Friedberg J.W., Ahn K.W., et al. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant. 2018;24(6):1163–71. DOI: 10.1016/j.bbmt.2017.12.771.

56. Locke F.L., Miklos D.B., Jacobson C.A., et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N Engl J Med. 2022;386(7):640– 54. DOI: 10.1056/NEJMoa2116133.

57. Shadman M., Caimi P.F., O’Brien S.M., et al. Efficacy and Safety of a Third Generation CD20 CAR-T (MB-106) for Treatment of Relapsed/Refractory Indolent B-Cell Non-Hodgkin Lymphoma: Phase-1 Results from a Multicenter Trial. Blood. 2023;142(Suppl. 1):2102. DOI: 10.1182/blood-2023-175007.

58. Shah N.N., Johnson B.D., Schneider D., et al. Bispecific anti-CD20, antiCD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nature Med. 2020;26(10):1569–75. DOI: 10.1038/s41591-020-1081-3.

59. Tong C., Zhang Y., Liu Y., et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma. Blood. 2020; 135 (14): 1632–44. DOI: 10.1182/blood.2020005278.

60. Locke F.L., Munoz J.L., Tees M.T., et al. ALLO-647 for Lymphodepletion in the Allogeneic CAR T Setting: Safety Experience with ALLO-501/501A in Patients (Pts) with Relapsed/Refractory (r/r) Large B-Cell and Follicular Lymphomas. Blood. 2023;142 (Suppl. 1):2095. DOI: 10.1182/blood-2023-189196.